Category: Endoscopic / Arthroscopic
Endoscopic / Arthroscopic
Covidien closes the $860 million acquisition of Given Imaging and its PillCam capsule endoscope.
Covidien (NYSE:COV) said it closed the buyout of Given Imaging and its PillCam imaging device for about $860 million, net of cash and investments.
EndoChoice can market its Fuse endoscopy system in Canada now that Health Canada has given the company clearance to sell the device.
EndoChoice said it won a marketing license in Canada for its Fuse endoscopy system.
The Fuse endoscope features 3 small cameras that provide a 330-degree view, nearly double the range of typical colonoscopy devices.
The Fuse device won FDA 510(k) clearance in the U.S. in June 2013.
Avantis brings in a $4.8 million debt round for its Third Eye colonoscopy endoscope.
Avantis Medical Systems said it brought in $4.8 million of a hoped-for $10.6 million debt round.
Sunnyvale, Calif.-based Avantis makes catheter-based endoscopic devices designed to detect and treat and gastrointestinal cancers, according to its website. It's flagship product is the Third Eye "retrospect" for colonoscopies.
Xlumena says it closed a $25 million Series C round as it pursues FDA clearance for its Axios stent and delivery system.
Xlumena said it closed a $25 million Series C round it plans to use to expand its commercial footprint and win FDA clearance for its Axios stent and delivery system.
Cantel Medical acquires Israel-based Jet Prep Ltd. and its FDA-cleared and CE-Marked Flushing Device.
Cantel Medical (NYSE:CMN) today announced the acquisition of Jet Prep Ltd, an endoscopy device company based in Herzliya, Israel.
Jet Prep is the developer of the Jet Prep Flushing Device, an endoscopic tool used for washing mucosal tissue in the gastrointestinal tract which already has regulatory clearances for the U.S. and E.U. markets.
Endoscopic surgical devices maker Medigus Ltd. touts a $7 million raise from investors in Israel and the U.S.
Israel-based Medigus closed a $7 million funding round, raised through sales of shares and options at about 20¢ apiece (NIS 0.72).
The sale, joined by investors in the U.S. as well as Israel, represents about 21% of the company's voting power combined with about 17.3 million 3-year options, according to a press release.
California weight-loss surgery systems maker USGI Medical lands FDA approval to launch what may be the largest pivotal study of its kind for an endoscopic weight-loss procedure.
USGI Medical will enroll up to 350 patients in an FDA-approved clinical trial of the g-Cath EZ suture anchor delivery catheter, an incision-free bariatric surgery technology that has already been used on more than 2,000 patients, mostly in Europe.